NanoGalaxy Platform
The NanoGalaxy platform encompasses a library of proprietary non-lipid, hydrophilic polymer nanoparticles (HNPs) that can selectively deliver genetic medicine payloads to the right tissues.
An in vivo platform to deliver genetic medicines
NanoGalaxy Platform Advantages
NanoGalaxy platform’s important advantages over competing technologies:
-
Extra-Hepatic Targeting with Predictable Design
Targeted delivery to specific cell types and tissues beyond the liver, powered by AI-driven analysis of structure-activity relationships
-
Programmable Immunogenicity
Tunable chemistry that can either induce immune tolerance or trigger immune activation
-
Payload Versatility
Compatibility with multiple genetic payloads, including mRNA, siRNA and DNA
-
Scalable Manufacturing
Chemically synthesizable nanoparticles that are suitable for large-scale manufacturing
Targeted Delivery
The NanoGalaxy® platform is a high-throughput engine designed to overcome the fundamental challenge of genetic medicine: targeted delivery. While traditional lipid nanoparticles (LNPs) are often sequestered by the liver, our library of proprietary Hydrophilic Nanoparticles (HNPs) is engineered to reach many tissues.
Structural Diversity & AI-Driven Discovery
We leverage the vast structural diversity of our HNP library to conduct iterative screening across multiple tissues. Our process is powered by AI-driven Structure-Activity Relationship (SAR) analysis, allowing us to:
-
Predict and Optimize
Use robust data models to predict nanoparticle behavior with high reliability.
-
Rapidly Iterate
Interrogate structural diversity at a scale previously impossible through manual screening.
-
Target Diverse Tissues
Select for specific delivery to the immune system, heart, lung and brain.
